Dermatology
Latest news
109 articles · 20 / page
Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs
Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and
Routine Whole‑Body Imaging Did Not Improve Early Survival in High‑Risk Melanoma: Interim TRIM Trial Analysis
Interim results from the multicentre phase 3 TRIM trial show no survival benefit from adding scheduled whole‑body CT or FDG‑PET‑CT to physical‑examination follow‑up after radical surgery for stage IIB–C and III cutaneous melanoma at median
SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes
A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-r
SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study
A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.
Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial
A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.
Comparative Efficacy and Safety of Treatments for Moderate to Severe Hidradenitis Suppurativa: Insights from a Living Network Meta-Analysis
This living systematic review and network meta-analysis evaluates efficacy, safety, and tolerability of medical treatments for moderate to severe hidradenitis suppurativa, highlighting top-performing agents and informing clinical decision-m
Oral Manifestations of Lamellar Ichthyosis: A Case Report of Two Siblings
Two brothers with lamellar ichthyosis presented with enamel defects and dental caries; dental rehabilitation with preventive measures was completed alongside dermatologic care.
Optimizing Scar Healing Post-Dermatologic Surgery: A Comparative Look at Hydrocolloid Dressings and Petroleum Ointments
This study evaluates whether a single application of hydrocolloid dressing improves scar appearance and reduces complications compared to daily petroleum ointment after dermatologic excisions.
Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety
The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.
Enhancing Surgical Outcomes: Hydrocolloid Dressings vs Petroleum Ointment for Scar Management
This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.
T-Cell Receptor Clonotypes as Prognostic Markers in Cutaneous T-Cell Lymphoma: Insights from Next-Generation Sequencing
This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-c
Baricitinib Shows Promising Results in Restoring Hair Growth in Adolescents with Severe Alopecia Areata: Phase 3 BRAVE-AA-PEDS Trial
The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases afte
Refining Sentinel Lymph Node Biopsy Decisions in Melanoma: Insights from the MERLIN_001 Gene Expression Profiling Study
The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized su
Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program
A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.
Prognostic Markers and Survival Outcomes in Advanced Mycosis Fungoides and Sézary Syndrome: Insights from the Cutaneous Lymphoma International Consortium
A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.
Large-Cell Transformation of Mycosis Fungoides: Clinical Patterns, Prognostic Insights, and Implications for Staging
Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.
CLIPI: A New Prognostic Index Transforming Risk Stratification in Advanced Cutaneous Lymphomas
The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.
Once-Daily Oral Icotrokinra vs Placebo and Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: Insights from ICONIC-ADVANCE 1 & 2 Phase 3 Trials
ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psoriasi
IL23R Polymorphism as a Genetic Predictor of Paradoxical Psoriasis in Anti-TNFα-Treated IBD Patients
The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.
Browse by specialty
Open language-specific specialty feeds and department pages.